keyword
MENU ▼
Read by QxMD icon Read
search

FEIBA

keyword
https://www.readbyqxmd.com/read/27850486/848-urgent-doac-reversal-with-low-20-units-kg-or-moderate-dose-%C3%A2-20-units-kg-feiba-in-major-bleeding
#1
William Dager, Aaron Roberts, William Dager
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27850258/619-use-of-activated-pcc-feiba-for-life-threatening-bleeding-associated-with-factor-xa-inhibitors
#2
Alicia Sacco, Sarah Young
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27795652/-antihemophilic-factor-is-not-the-only-answer-for-all-factor-viii-deficiencies-case-report-of-odontogenic-infection-in-a-patient-with-hemophilia-a-complicated-by-factor-viii-inhibitors-and-managed-by-transfusion-of-antihemophilic-factor-and-factor-viii-inhibitor
#3
K M Sudheesh, K S N Siva Bharani, H Y Kiran, Suresh Hanagavadi
Dental extraction in hemophiliacs with acquired inhibitors is always a risky procedure, which often presents a lot of problems associated with bleeding. A known case of hemophilia A complicated with factor VIII inhibitors and having odontogenic infection was successfully managed by transfusion of factor VIII inhibitor bypass activity (FEIBA) and antihemophilic factor. Past medical history was significant for multiple factor VIII transfusions. Bethesda assay done to identify inhibitors revealed low titer factor VIII inhibitors...
September 2016: Indian Journal of Dentistry
https://www.readbyqxmd.com/read/27642341/cost-effectiveness-analysis-of-biogeneric-recombinant-activated-factor-vii-aryoseven%C3%A2-and-activated-prothrombin-complex-concentrates-feiba%C3%A2-to-treat-hemophilia-a-patients-with-inhibitors-in-iran
#4
Mina Golestani, Peyman Eshghi, Hamid Reza Rasekh, Abdoll Majid Cheraghali, Jamshid Salamzadeh, Majid Naderi, Mohammad Reza Managhchi, Hamid Hoorfar, Gholam Reza Toogeh, Ali Imani, Mohammad Taghi Khodayari, Behnaz Habibpanah, Razieh Hantooshzadeh
Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost-effectiveness of FEIBA and AryoSeven® by Decision Analytic Model according to the Iranian healthcare system. An open label, multi-center, cross-over clinical trial was designed...
2016: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/27200453/-research-on-electrical-impedance-tomography-technology
#5
REVIEW
Feiba Chang, Hehua Zhang, Lexian Yan, Jun Yin
This article reviews the principle of electrical impedance tomography imaging and measurement system; focuses on electrical impedance tomography imaging detection system of incentive mode and several typical image reconstruction algorithm of electrical impedance imaging; and objectively compares and effectively evaluates several image reconstruction algorithm.
January 2016: Zhongguo Yi Liao Qi Xie za Zhi, Chinese Journal of Medical Instrumentation
https://www.readbyqxmd.com/read/26898225/rotem-monitoring-of-activated-and-non-activated-prothrombin-complex-concentrate-correction-of-dilutional-coagulopathy
#6
Olof Elvstam, Erik Berntorp, Ulf Schött
OBJECTIVES: Prothrombin complex concentrates have been used to correct dilutional coagulopathy, but many preparations contain anticoagulants, such as heparin, to counteract their prothrombotic effects. These anticoagulants can interfere with haemostatic assays. The aim of this study was to monitor two different prothrombin complex concentrates for the treatment of albumin dilution in vitro, using rotational thromboelastometry with or without the heparin-antagonising agent protamine. METHODS: Citrated blood from 10 healthy volunteers was, in vitro, diluted 1:1 with 5% albumin and then corrected with a four-factor prothrombin complex concentrate with heparin anticoagulant (Confidex®) corresponding to a clinical dose of 43 IU/kg...
2016: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/26879158/pro-and-anticoagulant-factors-facilitate-thrombin-generation-and-balance-the-haemostatic-response-to-feiba-%C3%A2-in-prophylactic-therapy
#7
K Varadi, S Tangada, M Loeschberger, P Montsch, G Schrenk, B Ewenstein, P L Turecek
INTRODUCTION: FEIBA(®) consists of zymogens and traces of activated forms of procoagulant factors II, VII, IX, X, anticoagulants protein C and TFPI, and small amounts of cofactors FV, FVIII and protein S, in a balanced ratio. As shown previously, FII-FXa complex plays a key role in FEIBA's mode of action (MoA). METHODS: Thrombin generation (TG) was measured by spiking coagulation factors, cofactors and inhibitors to high titer FVIII inhibitor plasma, and in plasma samples from patients in a phase 3 clinical study evaluating the safety and efficacy of FEIBA prophylaxis in haemophilia A patients with inhibitors...
July 2016: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/26842562/spanish-consensus-guidelines-on-prophylaxis-with-bypassing-agents-in-patients-with-haemophilia-and-inhibitors
#8
Maria Fernanda López-Fernández, Carmen Altisent Roca, Maria Teresa Álvarez-Román, Mariana Isabel Canaro Hirnyk, Maria Eva Mingot-Castellano, Víctor Jiménez-Yuste, Ana Rosa Cid Haro, Rosario Pérez-Garrido, Carmen Sedano Balbas
Prophylaxis with the blood clotting factor, factor VIII (FVIII) is ineffective for individuals with haemophilia A and high-titre inhibitors to FVIII. Prophylaxis with the FVIII bypassing agents activated prothrombin complex concentrates (aPCC; FEIBA® Baxalta) or recombinant activated factor VII (rFVIIa; Novo-Seven®, Novo Nordisk) may be an effective alternative. It was our aim to develop evidence -and expert opinion- based guidelines for prophylactic therapy for patients with high-titre inhibitors to FVIII...
May 2, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/26829366/global-post-authorization-safety-surveillance-study-real-world-data-on-prophylaxis-and-on-demand-treatment-using-feiba-an-activated-prothrombin-complex-concentrate
#9
Claude Negrier, Sophie Voisin, Fariba Baghaei, Robert Numerof, Aaron Novack, Jennifer E Doralt, Vadim Romanov, Alessandro Gringeri
This prospective, Post-Authorization Safety Surveillance (PASS) study was carried out in patients with hemophilia A or B and inhibitors treated with FEIBA for 1 year to collect real-world data on safety and effectiveness of FEIBA. The study followed a cohort design and did not make stipulations on treatment or observation schedule, as it was designed to observe routine medical practices based on physicians' treatment decisions, including whether patients received on-demand or prophylaxis with FEIBA. The attending physician maintained documentation, including medical records, laboratory reports, adverse event reports, and so on and a subject diary was used...
July 2016: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/26635073/recombinant-human-prothrombin-medi8111-prevents-bleeding-in-haemophilia-a-and-b-mice
#10
K M Hansson, A Lindblom, M Elg, A Lövgren
BACKGROUND: Haemophilia A and B are treated with FVIII and FIX replacement therapy. Treatment may be complicated by inhibitory antibodies that require bypass therapy such as FEIBA(®) in which prothrombin (FII) is suggested to be the main active component. METHODS: To evaluate the effect of FII on haemophilia recombinant human (rh) FII (MEDI8111) or plasma-derived human FII (pdhFII) was given as single doses to anaesthetized haemophilia A and B mice 3 min before tail transection and rhFVIII or rhFIX was used for comparison...
May 2016: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/26599794/optimizing-thrombin-generation-with-4-factor-prothrombin-complex-concentrates-in-neonatal-plasma-after-cardiopulmonary-bypass
#11
Sarah W Franklin, Fania Szlam, Janet D Fernandez, Traci Leong, Kenichi A Tanaka, Nina A Guzzetta
BACKGROUND: Bleeding is a serious complication after pediatric cardiopulmonary bypass (CPB) that is associated with an increase in perioperative morbidity and mortality. Four-factor prothrombin complex concentrates (4F-PCCs) have been used off-label to supplement transfusion protocols for bleeding after CPB in adults; however, data on their use in neonates are limited. In this study, we hypothesized that 4F-PCCs administered ex vivo to neonatal plasma after CPB will increase thrombin generation...
April 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/26570865/1204-activated-pcc-feiba-for-reversal-of-rivaroxaban-induced-life-threatening-bleeding-a-case-series
#12
Elizabeth Messana, Suprat Saely Wilson
No abstract text is available yet for this article.
December 2015: Critical Care Medicine
https://www.readbyqxmd.com/read/26545367/the-role-of-feiba-in-reversing-novel-oral-anticoagulants-in-intracerebral-hemorrhage
#13
Jamil R Dibu, Jonathan M Weimer, Christine Ahrens, Edward Manno, Jennifer A Frontera
BACKGROUND: Activated prothrombin complex concentrates factor eight inhibitor bypassing activity (FEIBA) has been recommended for reversing novel oral anticoagulants (NOAC) in the context of intracerebral hemorrhage (ICH), though few clinical studies report its use. METHODS: A prospective study of patients with spontaneous ICH was conducted from May 2013 to May 2015. Hospital complications including hemorrhage (gastrointestinal bleeding, anemia requiring transfusion, and surgical site bleeding) and thrombosis (pulmonary embolus, deep vein thrombosis, ischemic stroke, and myocardial infarction) were recorded...
June 2016: Neurocritical Care
https://www.readbyqxmd.com/read/26540130/-bleedings-under-noac-non-vitamin-k-dependent-oral-anticoagulants-evidence-and-practical-management
#14
J Koscielny, E Rutkauskaite
UNLABELLED: The doses of these drugs are barely tested and the potential clinical thromboembolic risk must be taken into account. Despite the widespread use of NOAC (non vitamin-K dependent oral anticoagulants) and recommendations of regulatory agencies and first consensus meeting on handling the bleeding situation under NOAC, especially in hospitals without a large hemostatic focus, uncertainty still exists. In case of mild bleeding from a clinical perspective, the medical care of these patients and the delay of the next dose or discontinuation is advised...
2015: Hämostaseologie
https://www.readbyqxmd.com/read/26505666/activated-prothrombin-complex-concentrate-feiba%C3%A2-for-the-treatment-and-prevention-of-bleeding-in-patients-with-acquired-haemophilia-a-sequential-study
#15
Ezio Zanon, Marta Milan, Gabriella Gamba, Chiara Ambaglio, Graziella Saggiorato, Luca Spiezia, Nadia Montani, Paolo Prandoni
Despite anti-haemorrhagic therapy with proper doses of activated prothrombin complex concentrate (aPCC, Feiba®), patients with acquired haemophilia A (AHA) have a considerable risk of recurrent bleeding complications. Evidence in support of the benefit-to-risk ratio of prevention strategies with the use of lower doses of aPCC following the end of the initial treatment period is scarce and inconclusive. We report our experience in the management of 18 consecutive patients with AHA admitted to two Haemophilia centres in Italy...
December 2015: Thrombosis Research
https://www.readbyqxmd.com/read/26399175/hepatitis-e-virus-and-the-safety-of-plasma-products-investigations-into-the-reduction-capacity-of-manufacturing-processes
#16
Maria R Farcet, Cornelia Lackner, Gerhard Antoine, Philip O Rabel, Andreas Wieser, Andreas Flicker, Ulrike Unger, Jens Modrof, Thomas R Kreil
BACKGROUND: Hepatitis E virus (HEV) has been transmitted by transfusion of labile blood products and the occasional detection of HEV RNA in plasma pools indicates that HEV viremic donations might enter the manufacturing process of plasma products. To verify the safety margins of plasma products with respect to HEV, virus reduction steps commonly used in their manufacturing processes were investigated for their effectiveness to reduce HEV. STUDY DESIGN AND METHODS: Detection methods for HEV removal (by reverse transcription quantitative polymerase chain reaction) and inactivation (using an infectivity assay) were established...
February 2016: Transfusion
https://www.readbyqxmd.com/read/26346326/refractory-epistaxis-due-to-severe-factor-v-deficiency-with-inhibitor
#17
Elizabeth S John, Minesh D Patel, Julio Hajdenberg
Factor V deficiency secondary to inhibitors is extremely rare and can be caused by a wide collection of exposures such as bovine thrombin and beta lactamase antibiotics. The management of factor V deficiency with inhibitor is a condition treated based on case reports due to the rarity of this condition. We describe a complicated case of an elderly patient with severe factor V deficiency with high inhibitor titer refractory to FEIBA (anti-inhibitor coagulation complex) treated with NovoSeven concurrently with cyclosporine immunosuppression and Rituxan...
2015: Case Reports in Hematology
https://www.readbyqxmd.com/read/26027293/-the-research-and-expectation-on-wearable-health-monitoring-system
#18
Feiba Chang, Jun Yin, Hehua Zhang, Lexian Yan, Shuying Li, Deqiang Zhou
Wearable health monitoring systems that use wearable biosensors capturing human motion and physiological parameters, to achieve the wearer's movement and health management needs. Wearable health monitoring system is a noninvasive continuous detection of human physiological information, data wireless transmission and real-time processing capabilities of integrated system, can satisfy physiological condition monitoring under the condition of low physiological and psychological load. This paper first describes the wearable health monitoring system structure and the relevant technology applied to wearable health monitoring system, and focuses on the current research work what we have done associated with wearable monitoring that wearable respiration and ECG acquisition and construction of electric multi-parameter body area network...
January 2015: Zhongguo Yi Liao Qi Xie za Zhi, Chinese Journal of Medical Instrumentation
https://www.readbyqxmd.com/read/25944555/effects-of-recombinant-human-prothrombin-on-thrombin-generation-in-plasma-from-patients-with-hemophilia-a-and-b
#19
COMPARATIVE STUDY
K M Hansson, D Gustafsson, T Skärby, L Frison, E Berntorp
BACKGROUND: The present study was carried out to investigate the impact of FII levels, and their increase, on the hemostatic potential in plasma from hemophilia A and B patients with and without inhibitors. METHOD: Recombinant human factor (F) II (rhFII) was added ex vivo to plasma from 68 patients with hemophilia A and B, with or without inhibitors. The hemostatic potential as measured by thrombin generation (calibrated automated thrombogram [CAT]) was focused on the endogenous thrombin potential (ETP) as it has been shown to correlate with the clinical phenotype of bleeding in hemophilia patients and has also been used to guide bypassing therapy in hemophilia patients with inhibitors before elective surgery...
July 2015: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/25926585/emergency-reversal-of-dabigatran-for-emergency-surgery
#20
Thomas Puttick, Rahul Bahl, Hussein Mohamedbhai
An 80-year-old woman had the anticoagulant effect of dabigatran etexilate reversed using factor eight inhibitor bypassing activity (FEIBA) in order to facilitate emergency surgery for an incarcerated femoral hernia. She had atrial fibrillation was taking the anticoagulant for stroke prevention. That afternoon her international normalised ratio (INR) was 1.3 and activated partial thromboplastin time ratio (APPTr) was 2.17, having taken dabigatran that morning. 3000 units of FEIBA and 10 mg of vitamin K were administered and she was taken to theatre for emergency surgery...
April 29, 2015: BMJ Case Reports
keyword
keyword
5300
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"